Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis-Reference-Cited by-同舟云学术

Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis

Published:2020-10-19 Issue:5 Volume:35 Page:1067-1076
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

Aimo Alberto^ORCID,Pateras Konstantinos,Stamatelopoulos Kimon,Bayes-Genis Antoni,Lombardi Carlo Mario,Passino Claudio,Emdin Michele,Georgiopoulos Georgios

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10557-020-07099-2.pdf

Reference31 articles.

1. Metra M, Teerlink JR. Heart failure. Lancet. 2017;390:1981–95.

2. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.

4. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61.

5. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883–93.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure;High Blood Pressure & Cardiovascular Prevention;2024-08-22

2. Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?;Heart Failure Reviews;2024-07-23

3. Sodium-glucose cotransporter type 2 inhibitors in the treatment of chronic heart failure: new evidence;Meditsinskiy sovet = Medical Council;2024-05-19

4. Comparative efficacy of vericiguat to sacubitril/valsartan for patients with heart failure reduced ejection fraction: Systematic review and network meta-analysis;International Journal of Cardiology;2024-04

5. Prognostic significance of serum dynamin‑related protein 1 in patients with heart failure: Findings from a prospective observational study;Experimental and Therapeutic Medicine;2024-01-29